您的位置: 首页 > 农业专利 > 详情页

VIRUS ENVELOPPE RESISTANT A L'INACTIVATION DU COMPLEMENT POUR LE TRAITEMENT DU CANCER
专利权人:
LLC;WELLSTAT IMMUNOTHERAPEUTICS
发明人:
LUO, TIANCI,MOLINA, RENE,CASTILLE, GABRIEL
申请号:
CA3026892
公开号:
CA3026892A1
申请日:
2018.05.10
申请国别(地区):
CA
年份:
2018
代理人:
摘要:
A recombinant fusion protein is disclosed. The fusion protein comprises: (a) a CD55 peptide sequence, (b) a linker sequence C-terminal to the CD55 sequence, (c) a transmembrane domain C-terminal to the linker sequence, and (d) an intracellular domain C-terminal to the transmembrane domain. The fusion protein does not contain a GPI anchor. The fusion protein can be expressed with an N-terminal secretory signal peptide, which is cleaved to yield the mature protein on the surface of a cell line or an enveloped virus. An oncolytic virus expressing the fusion protein is resistant to complement inactivation and can be used to treat cancer.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充